A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00215345|
Recruitment Status : Unknown
Verified September 2005 by Department of Veterans Affairs, New Jersey.
Recruitment status was: Recruiting
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Taxotere Drug: Celecoxib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||66 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer|
|Study Start Date :||August 2002|
|Study Completion Date :||December 2006|
- Determine the effect of Taxotere and celecoxib on PSA and objective response in patients with HRPC
- Evaluate the toxicity of the combination of celecoxib and Taxotere in patients with stage D3 prostate cancer.
- Determine the effects of this regimen on quality of life.
- Determine the survival of the patients treated
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00215345
|Contact: Basil Kasimis, MD||973-676-1000 ext email@example.com|
|United States, New Jersey|
|Department Of Veterans Affairs NJ Health Care System||Recruiting|
|East Orange, New Jersey, United States, 07018|
|Contact: Basil Kasimis, MD 973-676-1000 ext 1544 firstname.lastname@example.org|
|Sub-Investigator: Victor Chang, MD|
|Sub-Investigator: Shanthi Srinivas, MD|
|Sub-Investigator: Fengming Zhong, MD|
|Principal Investigator:||Basil Kasimis, MD||Department of Veterans Affairs NJ Health Care System|